Physician profile
Kenneth Pinna
NPI 1568423879
$56,262.50
in general payments reported to CMS, 2019-2025
28 companies · $2,051 in 2025
The $2,051 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,048 · 2020: $8,295 · 2021: $11K · 2022: $21K · 2023: $2,908 · 2024: $3,808 · 2025: $2,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,519 · Consulting Fee: $1,803 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,519.10 |
| Consulting Fee | $1,802.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
| Education | $144.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $36,874.60 | 2019-2025 | Nucala, Trelegy Ellipta |
| Shire North American Group INC | $5,702.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $2,705.03 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $2,536.46 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,408.49 | 2019-2025 | |
| Pfizer INC. | $1,215.84 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,008.42 | 2020-2025 | Hyqvia, Cuvitru, Glassia |
| Amgen INC. | $809.04 | 2022-2025 | Tezspire, Otezla |
| Genentech USA, INC. | $752.14 | 2019-2025 | Xolair |
| Csl Behring | $558.83 | 2019-2024 | Haegarda, Hizentra |
| Regeneron Pharmaceuticals, INC. | $558.77 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $538.32 | 2020-2025 | Xembify, Prolastin-C Liquid |
| Pharming Healthcare, INC. | $282.04 | 2019-2025 | Ruconest |
| Optinose US, INC. | $219.60 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $214.11 | 2020-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $135.66 | 2020-2021 | |
| Adma Biomanufacturing LLC | $116.88 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $102.09 | 2019-2024 | |
| Biocryst US Sales Co., LLC | $95.19 | 2021-2025 | Orladeyo |
| Mylan Specialty L.P. | $85.52 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.46 | 2020-2021 | |
| Blueprint Medicines Corporation | $55.00 | 2024-2025 | Ayvakit |
| Leo Pharma INC. | $54.66 | 2022-2025 | Adbry |
| Kedrion Biopharma, INC. | $44.85 | 2022-2024 | Rhogam Ultra-Filtered Plus, Kedrab, Albuked |
| Teva Pharmaceuticals USA, INC. | $39.28 | 2020 | |
| Abbvie INC. | $23.46 | 2023 | |
| Bio Products Laboratory USA, INC. | $23.07 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $22.27 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Pinna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.